AnalystsPaul JengPaul Jeng's Stock Forecasts
AnalystsPaul Jeng
Sectors:
Industries:
Analyst Ranking
Top 41%
#2085 out of 5177 analysts
Average Return
+25.56%
Win Rate
80%4 out of 5
Risk vs Reward
Poor
Good
Paul Jeng's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Immatics NvIMTX | +48.71% | $6.61 | $9.83 | 2025-09-17 - 2026-01-16 | Strong Buy |
Context Therapeutics IncCNTX | +44.00% | $1.00 | $1.44 | 2025-09-17 - 2026-01-16 | Strong Buy |
Ideaya Biosciences IncIDYA | +36.69% | $26.22 | $35.84 | 2025-09-17 - 2026-01-16 | Strong Buy |
Adagene IncADAG | +3.16% | $1.90 | $1.96 | 2025-11-23 - 2026-01-16 | Strong Buy |
Paul Jeng Analyst Color
Get additional color on Paul Jeng's coverage of popular stocks
Paul Jeng's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Adagene IncADAG | 1 | Strong Buy | $9.00 | +359.18% | Initiates Coverage On | 2 months ago |
Immatics NvIMTX | 2 | Strong Buy | $19.00 | +93.29% | Maintains | 2 months ago |
Context Therapeutics IncCNTX | 1 | Strong Buy | $5.00 | +247.22% | Initiates Coverage On | 4 months ago |
Ideaya Biosciences IncIDYA | 1 | Strong Buy | $50.00 | +39.51% | Initiates Coverage On | 4 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.